Skip to main content
SpringerLink
Log in

Management of Critically Ill Persons with COVID-19 and Diabetes

  • Chapter
  • First Online:
Diabetes and COVID-19

Part of the book series: Contemporary Endocrinology ((COE))

  • 132 Accesses

Abstract

COVID-19 disease poses a significant risk for critical illness, including hyperglycemic emergencies such as diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS), especially in patients with diabetes. While treatment with a continuous insulin infusion is traditionally considered to be the standard of care in DKA management, subcutaneous insulin protocols have been utilized during the pandemic for treating mild-to moderate DKA with the goal of reducing personal protective equipment use, intensive care unit bed utilization, and health-care worker exposure to and transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Subcutaneous insulin protocols for DKA generally use an initial basal insulin dose with rapid-acting insulin administered every 3–4 h. Due to the risk for acute respiratory distress syndrome and acute renal injury in COVID-19 disease, judicious fluid and electrolyte management is indicated. To help further reduce the need for potential viral exposure, early data suggests the clinical efficacy and safety of continuous glucose monitoring (CGM) in the management of critically ill patients with COVID-19 disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bertoni AG, Saydah S, Brancati FL. Diabetes and the risk of infection-related mortality in the U.S. Diabetes Care. 2001;24(6):1044–9. https://doi.org/10.2337/diacare.24.6.1044.

    Article  CAS  PubMed  Google Scholar 

  2. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002;87(3):978–82. https://doi.org/10.1210/jcem.87.3.8341.

    Article  CAS  PubMed  Google Scholar 

  3. Roberts GW, Quinn SJ, Valentine N, Alhawassi T, O’Dea H, Stranks SN, et al. Relative hyperglycemia, a marker of critical illness: introducing the stress hyperglycemia ratio. J Clin Endocrinol Metab. 2015;100(12):4490–7. https://doi.org/10.1210/jc.2015-2660.

    Article  CAS  PubMed  Google Scholar 

  4. Sathish T, Kapoor N, Cao Y, Tapp RJ, Zimmet P. Proportion of newly diagnosed diabetes in COVID-19 patients: a systematic review and meta-analysis. Diabetes Obes Metab. 2021;23(3):870–4. https://doi.org/10.1111/dom.14269.

    Article  CAS  PubMed  Google Scholar 

  5. Vasbinder A, Anderson E, Shadid H, Berlin H, Pan M, Azam TU, et al. Inflammation, hyperglycemia, and adverse outcomes in individuals with diabetes mellitus hospitalized for COVID-19. Diabetes Care. 2022;45(3):692–700. https://doi.org/10.2337/dc21-2102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Pazoki M, Keykhaei M, Kafan S, Montazeri M, Mirabdolhagh Hazaveh M, Sotoodehnia M, et al. Risk indicators associated with in-hospital mortality and severity in patients with diabetes mellitus and confirmed or clinically suspected COVID-19. J Diabetes Metab Disord. 2021;20(1):59–69. https://doi.org/10.1007/s40200-020-00701-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Alahmad B, Al-Shammari AA, Bennakhi A, Al-Mulla F, Ali H. Fasting blood glucose and COVID-19 severity: nonlinearity matters. Diabetes Care. 2020;43(12):3113–6. https://doi.org/10.2337/dc20-1941.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Mantovani A, Byrne CD, Zheng MH, Targher G. Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: a meta-analysis of observational studies. Nutr Metab Cardiovasc Dis. 2020;30(8):1236–48. https://doi.org/10.1016/j.numecd.2020.05.014.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47(3):193–9. https://doi.org/10.1007/s00592-009-0109-4.

    Article  CAS  PubMed  Google Scholar 

  10. Coate KC, Cha J, Shrestha S, Wang W, Goncalves LM, Almaca J, et al. SARS-CoV-2 cell entry factors ACE2 and TMPRSS2 are expressed in the microvasculature and ducts of human pancreas but are not enriched in beta cells. Cell Metab. 2020;32(6):1028–40 e4. https://doi.org/10.1016/j.cmet.2020.11.006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Kusmartseva I, Wu W, Syed F, Van Der Heide V, Jorgensen M, Joseph P, et al. Expression of SARS-CoV-2 entry factors in the pancreas of Normal organ donors and individuals with COVID-19. Cell Metab. 2020;32(6):1041–51 e6. https://doi.org/10.1016/j.cmet.2020.11.005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Wu CT, Lidsky PV, Xiao Y, Lee IT, Cheng R, Nakayama T, et al. SARS-CoV-2 infects human pancreatic beta cells and elicits beta cell impairment. Cell Metab. 2021;33(8):1565–76 e5. https://doi.org/10.1016/j.cmet.2021.05.013.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Muller JA, Gross R, Conzelmann C, Kruger J, Merle U, Steinhart J, et al. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat Metab. 2021;3(2):149–65. https://doi.org/10.1038/s42255-021-00347-1.

    Article  CAS  PubMed  Google Scholar 

  14. Eskandarani RM, Sawan S. Diabetic ketoacidosis on hospitalization with COVID-19 in a previously nondiabetic patient: a review of pathophysiology. Clin Med Insights Endocrinol Diabetes. 2020;13:1179551420984125. https://doi.org/10.1177/1179551420984125.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Boddu SK, Aurangabadkar G, Kuchay MS. New onset diabetes, type 1 diabetes and COVID-19. Diabetes Metab Syndr. 2020;14(6):2211–7. https://doi.org/10.1016/j.dsx.2020.11.012.

    Article  PubMed  PubMed Central  Google Scholar 

  16. COVID-19 Treatment Guidelines Panel Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/ (2022). Accessed April 15 2022.

  17. Kahn CRFH, O’Neill BT. Williams textbook of endocrinology. In: Pathophysiology of type 2 diabetes mellitus. 14th ed. Elsevier; 2020.

    Google Scholar 

  18. Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. Lancet. 2009;373(9677):1798–807. https://doi.org/10.1016/S0140-6736(09)60553-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Inzucchi SE. Clinical practice. Management of hyperglycemia in the hospital setting. N Engl J Med. 2006;355(18):1903–11. https://doi.org/10.1056/NEJMcp060094.

    Article  CAS  PubMed  Google Scholar 

  20. American Diabetes Association Professional Practice C, American Diabetes Association Professional Practice C, Draznin B, Aroda VR, Bakris G, Benson G, et al. 16. Diabetes Care in the Hospital: standards of medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S244–S53. https://doi.org/10.2337/dc22-S016.

    Article  Google Scholar 

  21. Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32(6):1119–31. https://doi.org/10.2337/dc09-9029.

    Article  PubMed  PubMed Central  Google Scholar 

  22. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345(19):1359–67. https://doi.org/10.1056/NEJMoa011300.

    Article  PubMed  Google Scholar 

  23. Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354(5):449–61. https://doi.org/10.1056/NEJMoa052521.

    Article  PubMed  Google Scholar 

  24. Investigators N-SS, Finfer S, Chittock DR, Su SY, Blair D, Foster D, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360(13):1283–97. https://doi.org/10.1056/NEJMoa0810625.

    Article  Google Scholar 

  25. Kansagara D, Fu R, Freeman M, Wolf F, Helfand M. Intensive insulin therapy in hospitalized patients: a systematic review. Ann Intern Med. 2011;154(4):268–82. https://doi.org/10.7326/0003-4819-154-4-201102150-00008.

    Article  PubMed  Google Scholar 

  26. Sathya B, Davis R, Taveira T, Whitlatch H, Wu W-C. Intensity of peri-operative glycemic control and postoperative outcomes in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2013;102(1):8–15. https://doi.org/10.1016/j.diabres.2013.05.003.

    Article  CAS  PubMed  Google Scholar 

  27. Furnary AP, Gao G, Grunkemeier GL, Wu Y, Zerr KJ, Bookin SO, et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2003;125(5):1007–21. https://doi.org/10.1067/mtc.2003.181.

    Article  CAS  PubMed  Google Scholar 

  28. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ. 1997;314(7093):1512–5. https://doi.org/10.1136/bmj.314.7093.1512.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Benoit SR, Hora I, Pasquel FJ, Gregg EW, Albright AL, Imperatore G. Trends in emergency department visits and inpatient admissions for hyperglycemic crises in adults with diabetes in the U.S., 2006-2015. Diabetes Care. 2020;43(5):1057–64. https://doi.org/10.2337/dc19-2449.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Scott AR. Joint British diabetes societies for inpatient C, group Jhhg. Management of hyperosmolar hyperglycaemic state in adults with diabetes. Diabet Med. 2015;32(6):714–24. https://doi.org/10.1111/dme.12757.

    Article  CAS  PubMed  Google Scholar 

  31. Umpierrez G, Korytkowski M. Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol. 2016;12(4):222–32. https://doi.org/10.1038/nrendo.2016.15.

    Article  CAS  PubMed  Google Scholar 

  32. Pasquel FJ, Tsegka K, Wang H, Cardona S, Galindo RJ, Fayfman M, et al. Clinical outcomes in patients with isolated or combined diabetic ketoacidosis and hyperosmolar hyperglycemic state: a retrospective, Hospital-Based Cohort Study. Diabetes Care. 2020;43(2):349–57. https://doi.org/10.2337/dc19-1168.

    Article  CAS  PubMed  Google Scholar 

  33. Palermo NE, Sadhu AR, McDonnell ME. Diabetic ketoacidosis in COVID-19: unique concerns and considerations. J Clin Endocrinol Metab. 2020;105(8):2819. https://doi.org/10.1210/clinem/dgaa360.

    Article  Google Scholar 

  34. Reddy PK, Kuchay MS, Mehta Y, Mishra SK. Diabetic ketoacidosis precipitated by COVID-19: a report of two cases and review of literature. Diabetes Metab Syndr. 2020;14(5):1459–62. https://doi.org/10.1016/j.dsx.2020.07.050.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Li J, Wang X, Chen J, Zuo X, Zhang H, Deng A. COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes Metab. 2020;22(10):1935–41. https://doi.org/10.1111/dom.14057.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020;63(8):1500–15. https://doi.org/10.1007/s00125-020-05180-x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Barrett CE, Park J, Kompaniyets L, Baggs J, Cheng YJ, Zhang P, et al. Intensive care unit admission, mechanical ventilation, and mortality among patients with type 1 diabetes hospitalized for COVID-19 in the U.S. Diabetes Care. 2021;44(8):1788–96. https://doi.org/10.2337/dc21-0604.

    Article  CAS  PubMed  Google Scholar 

  38. Misra S, Barron E, Vamos E, Thomas S, Dhatariya K, Kar P, et al. Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study. Lancet Diabetes Endocrinol. 2021;9(10):671–80. https://doi.org/10.1016/S2213-8587(21)00208-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Chamorro-Pareja N, Parthasarathy S, Annam J, Hoffman J, Coyle C, Kishore P. Letter to the editor: unexpected high mortality in COVID-19 and diabetic ketoacidosis. Metabolism. 2020;110:154301. https://doi.org/10.1016/j.metabol.2020.154301.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Stevens JS, Bogun MM, McMahon DJ, Zucker J, Kurlansky P, Mohan S, et al. Diabetic ketoacidosis and mortality in COVID-19 infection. Diabetes Metab. 2021;47(6):101267. https://doi.org/10.1016/j.diabet.2021.101267.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Pasquel FJ, Messler J, Booth R, Kubacka B, Mumpower A, Umpierrez G, et al. Characteristics of and mortality associated with diabetic ketoacidosis among US patients hospitalized with or without COVID-19. JAMA Netw Open. 2021;4(3):e211091-e. https://doi.org/10.1001/jamanetworkopen.2021.1091.

    Article  Google Scholar 

  42. Benoit SRZY, Geiss LS, Gregg EW, Albright A. Trends in diabetic ketoacidosis hospitalizations and in-hospital mortality — United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2018;67(12):362–5. https://doi.org/10.15585/mmwr.mm6712a3.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Armeni E, Aziz U, Qamar S, Nasir S, Nethaji C, Negus R, et al. Protracted ketonaemia in hyperglycaemic emergencies in COVID-19: a retrospective case series. Lancet Diabetes Endocrinol. 2020;8(8):660–3. https://doi.org/10.1016/S2213-8587(20)30221-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Shah A, Deak A, Allen S, Silfani E, Koppin C, Zisman-Ilani Y, et al. Some characteristics of hyperglycaemic crisis differ between patients with and without COVID-19 at a safety-net hospital in a cross-sectional study. Ann Med. 2021;53(1):1642–5. https://doi.org/10.1080/07853890.2021.1975042.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Tran TTT, Pease A, Wood AJ, Zajac JD, Martensson J, Bellomo R, et al. Review of evidence for adult diabetic ketoacidosis management protocols. Front Endocrinol (Lausanne). 2017;8:106. https://doi.org/10.3389/fendo.2017.00106.

    Article  PubMed  Google Scholar 

  46. Self WH, Evans CS, Jenkins CA, Brown RM, Casey JD, Collins SP, et al. Clinical effects of balanced crystalloids vs saline in adults with diabetic ketoacidosis: a subgroup analysis of cluster randomized clinical trials. JAMA Netw Open. 2020;3(11):e2024596. https://doi.org/10.1001/jamanetworkopen.2020.24596.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335–43. https://doi.org/10.2337/dc09-9032.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Heber D, Molitch ME, Sperling MA. Low-dose continuous insulin therapy for diabetic ketoacidosis. Prospective comparison with “conventional” insulin therapy. Arch Intern Med. 1977;137(10):1377–80.

    Article  CAS  PubMed  Google Scholar 

  49. Fisher JN, Shahshahani MN, Kitabchi AE. Diabetic ketoacidosis: low-dose insulin therapy by various routes. N Engl J Med. 1977;297(5):238–41. https://doi.org/10.1056/NEJM197708042970502.

    Article  CAS  PubMed  Google Scholar 

  50. Umpierrez GE, Cuervo R, Karabell A, Latif K, Freire AX, Kitabchi AE. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care. 2004;27(8):1873–8. https://doi.org/10.2337/diacare.27.8.1873.

    Article  CAS  PubMed  Google Scholar 

  51. Umpierrez GE, Latif K, Stoever J, Cuervo R, Park L, Freire AX, et al. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. Am J Med. 2004;117(5):291–6. https://doi.org/10.1016/j.amjmed.2004.05.010.

    Article  CAS  PubMed  Google Scholar 

  52. Andrade-Castellanos CA, Colunga-Lozano LE, Delgado-Figueroa N, Gonzalez-Padilla DA. Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis. Cochrane Database Syst Rev. 2016;1:CD011281. https://doi.org/10.1002/14651858.CD011281.pub2.

    Article  Google Scholar 

  53. Rao P, Jiang SF, Kipnis P, Patel DM, Katsnelson S, Madani S, et al. Evaluation of outcomes following hospital-wide implementation of a subcutaneous insulin protocol for diabetic ketoacidosis. JAMA Netw Open. 2022;5(4):e226417. https://doi.org/10.1001/jamanetworkopen.2022.6417.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Agarwal SCJ, Tomer Y Montefiore Subcutaneous Insulin DKA Protocol. https://professional.diabetes.org/sites/professional.diabetes.org/files/media/ada-montefiore_dka_protcol_version_3.0_5_22_20.pdf. Accessed April 15 2022.

  55. Lam DLE, Leter A, Levy C, O’Malley G, Radparvar S, Shah N: MSHS COVID-19 DKA Protocol. https://professional.diabetes.org/sites/professional.diabetes.org/files/media/mshs_covid_dka_protocol.pdf (2022). Accessed April 15 2022.

  56. Group NIDC-R: Guideline for managing DKA using subcutaneous insulin. https://www.diabetes.org.uk/resources-s3/public/2020-04/COvID_DKA_SC_v3.2.pdf (2022). Accessed April 15 2022.

  57. Agarwal S, Mathew J, Davis GM, Shephardson A, Levine A, Louard R, et al. Continuous glucose monitoring in the intensive care unit during the COVID-19 pandemic. Diabetes Care. 2021;44(3):847–9. https://doi.org/10.2337/dc20-2219.

    Article  CAS  PubMed  Google Scholar 

  58. Sadhu AR, Serrano IA, Xu J, Nisar T, Lucier J, Pandya AR, et al. Continuous glucose monitoring in critically ill patients with COVID-19: results of an emergent pilot study. J Diabetes Sci Technol. 2020;14(6):1065–73. https://doi.org/10.1177/1932296820964264.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Faulds ER, Boutsicaris A, Sumner L, Jones L, McNett M, Smetana KS, et al. Use of continuous glucose monitor in critically ill COVID-19 patients requiring insulin infusion: an observational study. J Clin Endocrinol Metab. 2021;106(10):e4007–e16. https://doi.org/10.1210/clinem/dgab409.

    Article  PubMed  Google Scholar 

  60. Davis GM, Faulds E, Walker T, Vigliotti D, Rabinovich M, Hester J, et al. Remote continuous glucose monitoring with a computerized insulin infusion protocol for critically ill patients in a COVID-19 medical ICU: proof of concept. Diabetes Care. 2021;44(4):1055–8. https://doi.org/10.2337/dc20-2085.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Bailey TS, Alva S. Landscape of continuous glucose monitoring (CGM) and integrated CGM: accuracy considerations. Diabetes Technol Ther. 2021;23(S3):S5–S11. https://doi.org/10.1089/dia.2021.0236.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Department of Medicine, The Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA

    Justin Mathew & Hanna J. Lee

Authors
  1. Justin Mathew
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hanna J. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hanna J. Lee .

Editor information

Editors and Affiliations

  1. Division of Endocrinology, Department of Medicine, Montefiore Einstein, Bronx, NY, USA

    Alyson K. Myers

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mathew, J., Lee, H.J. (2023). Management of Critically Ill Persons with COVID-19 and Diabetes. In: Myers, A.K. (eds) Diabetes and COVID-19. Contemporary Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-031-28536-3_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-28536-3_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-28535-6

  • Online ISBN: 978-3-031-28536-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation